Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

By L. Klareskog, D. van der Heijde, J. de Jager, A. Gough, J. Kalden, M. Malaise, E. Martín Mola, K. Pavelka, J. Sany, L. Settas and 4 more. The Lancet, 2004

1,864 citations recorded by the source corpus.

Subfields: Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/80193baf1603dfda4be863020279468a86e5cb49

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

I. McInnes

In Rheumatology

Citations in the corpus

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. (2004, result): “In patients with more advanced RA, results from a recent trial show the advantages of the combination of etanercept and MTX over either drug alone in terms of reducing disease activity, slowing radiographic progression of joint damage, and improving physical function (33).”
An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. (2008, background): “(%) of patients Painful joint count 12 (3) 1 (10) 3.”
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study (2009, result): “3 prior DMARDs, ACR20/ 50/70 responses were similar for etanercept and methotrexate (dosing similar to this study), with significance for etanercept superiority seen using the numeric ACRn response area under the curve.(19) Lastly, in PREMIER, where patients had early RA, shorter disease duration (,”
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. (2006, background): “This has been shown with traditional DMARDs as well as with biologic therapies (31,32).”
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010, positive): “2 53 MTX is considered the anchor drug in RA, 54 both on the basis of its efﬁ cacy as monotherapy and on the basis of its ability to increase the efﬁ cacy of biological DMARDs when used in combination, 55–59 as well as the beneﬁ cial long-term safety proﬁ le.”